Logo

CRVO

CervoMed Inc.

CRVO

CervoMed Inc. • NASDAQ
$9.94 ▲ 0.00% (+0.00)
Market Cap $91.97 M
52w High $16.94
52w Low $1.80
Dividend Yield 0%
P/E -3.43
Volume 57.93K
Outstanding Shares 9.25M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $322.569K ▲ $8.367M ▲ $-7.727M ▼ -2.395K% ▼ $-0.84 ▼ $-7.727M ▼
Q2-2025 $0 $6.616M ▲ $-6.258M ▼ 0% $-0.7 ▼ $-6.616M ▼
Q1-2025 $0 $5.303M ▼ $-4.894M ▲ 0% $-0.56 ▲ $-5.303M ▲
Q4-2024 $0 $7.241M ▲ $-6.706M ▼ 0% $-0.77 ▼ $-7.241M ▼
Q3-2024 $0 $5.396M $-4.754M 0% $-0.55 $-5.396M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $27.294M ▼ $30.611M ▼ $4.599M ▼ $26.011M ▼
Q2-2025 $33.531M ▼ $38.081M ▼ $4.642M ▲ $33.44M ▼
Q1-2025 $35.245M ▼ $38.577M ▼ $3.943M ▲ $34.634M ▼
Q4-2024 $38.922M ▼ $43.082M ▼ $3.879M ▲ $39.202M ▼
Q3-2024 $46.657M $48.884M $3.246M $45.637M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.727M ▼ $-6.465M ▲ $7.582M ▲ $0 ▼ $1.117M ▲ $-6.465M ▲
Q2-2025 $-6.258M ▼ $-6.515M ▼ $-254.993K ▼ $4.589M ▲ $-2.181M ▼ $-6.515M ▼
Q1-2025 $-4.894M ▲ $-3.894M ▲ $5.397M ▼ $0 $1.502M ▲ $-3.894M ▲
Q4-2024 $-6.706M ▼ $-8.051M ▼ $9.307M ▲ $0 ▲ $1.256M ▲ $-8.051M ▼
Q3-2024 $-4.754M $-4.855M $2.602M $-13.34K $-2.266M $-4.855M

Five-Year Company Overview

Income Statement

Income Statement CervoMed’s income statement looks like a typical early-stage biotech: essentially no meaningful revenue and a steady pattern of operating losses. The company is still very much in the “development and clinical trial” phase rather than the “commercial sales” phase. Losses appear driven by research, development, and overhead rather than by any failing product line, because there is no real product revenue yet. Reported earnings per share have swung sharply, but that is largely a function of repeated reverse stock splits, not a sudden change in the underlying business performance.

Balance Sheet

Balance Sheet The balance sheet is very light and simple. Assets are small and mostly made up of cash, with only a thin capital cushion supporting the business. Debt has essentially been reduced to negligible levels, which lowers financial risk but also highlights how dependent the company is on equity financing. Equity recently moved back into positive territory after having been negative, suggesting past recapitalizations and restructuring to keep the company funded. Overall, the balance sheet is lean, with limited room to absorb large setbacks without raising new capital.

Cash Flow

Cash Flow Cash flow reflects the profile of a small clinical-stage biotech: cash going out steadily to fund operations and almost nothing coming in from customers. Operating cash burn has been consistent but modest in absolute size, and there is virtually no spending on physical assets, which is normal for a science-driven business. There is no sign of the company generating self-sustaining cash; the model clearly depends on periodic external funding to support trials and overhead. As development moves toward larger, more expensive late-stage studies, the existing cash flow profile suggests that additional financing will likely be needed to maintain momentum.

Competitive Edge

Competitive Edge CervoMed’s competitive position rests on a narrow but distinctive focus: a single, novel drug candidate targeting brain inflammation in dementia with Lewy bodies. The company is trying to lead a new therapeutic niche by aiming at an enzyme involved in neuroinflammation rather than the more crowded approaches aimed at toxic proteins. Positive mid-stage clinical data in this specific dementia segment offers some differentiation and a potential first-mover advantage. At the same time, the company is small, with limited resources, competing in a field where large pharmaceutical firms and other biotechs are also pursuing neurodegenerative targets. Its concentration in one core asset creates both strategic clarity and substantial single-drug risk.

Innovation and R&D

Innovation and R&D Innovation and R&D are clearly the heart of CervoMed. The lead drug, neflamapimod, uses a targeted mechanism to address synaptic dysfunction by inhibiting a specific brain enzyme linked to inflammation, which is scientifically differentiated from many current dementia approaches. Early clinical results in dementia with Lewy bodies have been encouraging, and the company is preparing for a pivotal late-stage trial while also exploring use in other neurological conditions. Intellectual property protection extending late into the next decade adds some durability to the strategy if the drug succeeds. However, the entire R&D story is heavily concentrated in this one mechanism, so the main scientific and clinical risks are tightly tied to whether neflamapimod can reproduce strong results in larger, more rigorous trials.

Summary

Overall, CervoMed looks like a classic clinical-stage biotech: very little current commercial activity, a lean balance sheet, steady cash burn, and most of its potential value bound up in one lead drug. Financial statements show a company that survives through external funding rather than internal cash generation. Strategically, its focus on neuroinflammation in dementia with Lewy bodies and positive mid-stage data provide a distinct scientific angle and a credible path to a pivotal trial. The flip side is high concentration risk, substantial clinical and regulatory uncertainty, and an ongoing need for capital as development advances. Future outcomes will be driven far more by trial results, regulatory decisions, and partnering or financing success than by recent historical financial performance.

NEWS

November 24, 2025 · 7:00 AM UTC

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Read more

October 20, 2025 · 8:00 AM UTC

CervoMed to Present at the Emerging Growth Conference

Read more

October 8, 2025 · 7:00 AM UTC

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Read more

October 2, 2025 · 8:00 AM UTC

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Read more

September 17, 2025 · 7:30 AM UTC

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Read more